Brief: Heart Test Laboratories Inc Says Myovista Fda De Novo Resubmission Expected In Current Fiscal Year
01/08/2022 15:34
Aug 1 (Reuters) - Heart Test Laboratories Inc HSCS.O :
* HEARTSCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FISCAL
2022
FINANCIAL RESULTS
* HEART TEST LABORATORIES INC - MYOVISTA FDA DE NOVO
RESUBMISSION
EXPECTED IN CURRENT FISCAL YEAR
* HEART TEST LABORATORIES INC - THERE WERE NO MEANINGFUL
REVENUES
FOR FISCAL YEARS 2022 AND 2021
Source text for Eikon: ID:nGNXbrNQg4
Further company coverage: HSCS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on HeartSciences
See all newsBrief: Heartsciences Files Definitive Proxy Statement For Proposed Business Combination With Fortitude Mining
Brief: Fortitude Provides Second Quarter 2026 Financial And Operating Highlights
Brief: Fortitude Invests $1.0 Million In Heartsciences At A 22% Premium With No Adjustment To The Merger Consideration
Brief: Heartsciences - Files Preliminary Proxy For Business Combination With Fortitude Mining Holdings
Brief: Heartsciences Signs First Saas Revenues Agreement Following Full Launch Of Myovista Insights™